MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


Kelso invests £1.8 million in CVS deeming vet sector undervalued

ALN

Kelso Group Holdings PLC said on Tuesday it purchased £1.8 million worth of shares in CVS Group PLC, as the listed acquisition vehicle praised the veterinary company’s ‘consistent’ growth.

The London-based acquisition vehicle said it bought 130,000 shares of CVS at an average price of £13.87 in ‘recent weeks’.

Kelso said that since CVS’s listing on AIM in 2007, ‘its market capitalisation has grown to just under £1 billion, representing one of London Stock Exchange’s most consistent long-term growth stories’.

CVS Group is a provider of veterinary services in the UK and Australia, and currently operates about 470 practices in the two countries, employing around 2,300 veterinary surgeons and over 3,000 nurses.

Kelso said that CVS’s current valuation ‘presents a compelling opportunity’ given the company’s ‘strong balance sheet, with net debt of around £160 million as at December 31, alongside forecast earning before interest, taxes, depreciation, and amortisation of around £140 million for the year to June 30 2026 and robust cash generation’.

The lease capitalisation under the 2016 International Financial Reporting Standards would also support ‘moderately higher leverage’ which could be used ‘both to enhance shareholders returns and to mitigate potential interest from private equity fund investors’, Kelso said.

The acquisition vehicle also believes that the upcoming completion of the UK Competition & Markets Authority’s market investigation into veterinary services for household pets ‘should not present a huge impediment to CVS’s business model in the UK’.

Kelso Chair Nigel Knowles said: ‘We believe disciplined capital allocation will be increasingly important in unlocking future shareholder value. Kelso is a supportive long-term shareholder, and we look forward to engaging constructively with management over time. Our objective is to see CVS continue to develop as a UK-listed success story and to ensure that shareholders fully benefit from this potential.’

Kelso shares were down 6.9% to 2.70 pence each in London on Tuesday afternoon. CVS Group shares were up 1.9% at 1,410.00 pence.

Copyright 2026 Alliance News Ltd. All Rights Reserved.